Highlights

  • 4DMedical shares skyrocketed 30.67% on 25 March 2026, reaching AUD 6.05 following a landmark clinical update.
  • Mayo Clinic adopts CT:VQ technology for advanced ventilation and perfusion lung analysis.
  • Sixth elite U.S. Academic Medical Center to integrate the platform, joining the likes of Cleveland Clinic and Stanford.
  • Rapid commercial scaling achieved with six major institutional deployments within just seven months of FDA clearance.
  • Strategic validation from the world’s top-ranked hospital signals a potential shift in global respiratory diagnostic standards.

4DMedical Limited (ASX:4DX) witnessed an extraordinary surge in investor demand during the afternoon session on 25 March 2026, with its share price jumping 30.67% to AUD 6.05. The medical technology leader has delivered a staggering 1580.56% return over the past year, fueled by consistent North American commercial milestones.

The latest rally is tied to an agreement with the Mayo Clinic—consistently recognized as the premier hospital in the United States—to deploy 4DMedical’s CT:VQ software.

Elite Institutional Endorsement Drives Momentum

The deployment at Mayo Clinic marks a pivotal moment in 4DMedical’s global commercial strategy. By integrating CT:VQ into its clinical workflows, Mayo Clinic joins a prestigious group of U.S. Academic Medical Centers (AMCs) including Stanford, University of Miami, Cleveland Clinic, UC San Diego Health, and University of Chicago Medicine.

This expansion means the technology is now established at six of the most influential healthcare institutions in the country, providing a powerful reference network for broader market penetration. The current arrangement allows Mayo’s clinical teams to utilize CT:VQ for detailed lung analysis, building institutional familiarity with the software’s diagnostic outputs. While the initial 90-day term is not considered financially material on its own, the endorsement from a global leader in medical excellence is viewed as a game-changing catalyst for future commercial contracts and standard-of-care adoption.

Accelerating the New Standard in Lung Imaging

4DMedical’s CT:VQ technology is rapidly gaining traction due to its ability to provide high-resolution ventilation and perfusion data without the need for radioisotopes or contrast agents. This workflow efficiency allows hospitals to use existing CT infrastructure to gain functional insights that were previously only available through more complex nuclear medicine procedures. The pace of adoption has been described as unprecedented, with six top-tier institutional deployments secured in approximately seven months since receiving FDA clearance in September 2025. This momentum is further bolstered by the company’s existing distribution partnership with Philips and a growing sales pipeline, positioning the platform to redefine cardiothoracic imaging protocols across the U.S. healthcare system.

Management Commentary

4DMedical MD/CEO and Founder, Andreas Fouras, characterized the Mayo Clinic deployment as a "landmark moment" for the company. He noted that when the world’s top-ranked hospital chooses to implement a technology, it provides the strongest possible validation of clinical readiness and value.

Mr. Fouras highlighted that no other technology in the respiratory imaging space has achieved this level of elite clinical adoption in such a concentrated timeframe, creating what he described as an "unassailable platform" for future growth.

What This Means for Investors?

The massive share price reaction underscores the market's view of Mayo Clinic as the "gold standard" of endorsements. Investors are increasingly pricing in 4DMedical's transition from a research-phase med-tech firm to a commercially integrated provider within the lucrative U.S. hospital market.

With the pilot plant and AMC deployments providing a steady stream of clinical data, the focus now shifts to the conversion of these elite reference sites into long-term, high-volume commercial contracts.

Frequently Asked Questions (FAQs)

1.Why did 4DMedical (ASX:4DX) shares surge over 30% on 25 March 2026?

The stock rose sharply following the announcement that Mayo Clinic, the top-ranked hospital in the U.S., has begun deploying 4DMedical's CT:VQ™ respiratory imaging technology.

2.What is CT:VQ™ and why is it significant?

CT:VQ™ is a software solution that provides ventilation and perfusion analysis from standard CT scans without using radioisotopes. Its adoption by six major U.S. medical centers in seven months signals strong clinical demand.

  1. How many U.S. Academic Medical Centers are now using 4DMedical technology?

With the addition of Mayo Clinic, there are now six elite U.S. institutions utilizing the technology, including Stanford and Cleveland Clinic.